0001209191-18-008609.txt : 20180208 0001209191-18-008609.hdr.sgml : 20180208 20180208203922 ACCESSION NUMBER: 0001209191-18-008609 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180206 FILED AS OF DATE: 20180208 DATE AS OF CHANGE: 20180208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Amanullah Ashraf CENTRAL INDEX KEY: 0001670631 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37378 FILM NUMBER: 18587360 MAIL ADDRESS: STREET 1: C/O ATYR PHARMA, INC. STREET 2: 3545 JOHN HOPKINS COURT, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: aTYR PHARMA INC CENTRAL INDEX KEY: 0001339970 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 203435077 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-731-8389 MAIL ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-02-06 0 0001339970 aTYR PHARMA INC LIFE 0001670631 Amanullah Ashraf 3545 JOHN HOPKINS COURT, SUITE #250 SAN DIEGO CA 92121 0 1 0 0 See Remarks Common Stock 2018-02-07 4 M 0 3334 0.00 A 3334 D Common Stock 2018-02-08 4 S 0 1402 3.40 D 1932 D Employee Stock Option (right to buy) 3.30 2018-02-06 4 A 0 100000 0.00 A 2028-02-06 Common Stock 100000 100000 D Restricted Stock Units 0.00 2018-02-07 4 M 0 3334 0.00 D Common Stock 3334 6666 D Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 7, 2017. Sale made by the Reporting Person in compliance with the provisions of Rule 10b5-1 to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 7, 2017. The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 6, 2018, such that this option will be fully exercisable on February 6, 2022. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. The RSU grant vests as to one-third (1/3) of the total number of units on each one year anniversary of the grant commencing on February 7, 2018. Senior Vice President, Biologics Development and Manufacturing Nancy D. Krueger, Attorney-In-Fact 2018-02-08